NYSE Euronext accueille EOS imaging sur son marché européen


Paris, 16 February 2012– EOS imaging (FR0011191766 – EOSI), the pioneer in 2D/3D orthopaedic medical imaging, today celebrated its listing on NYSE Euronext in Paris.

The EOS imaging group designs, develops and markets EOS®, a medical imaging system that has revolutionised the care and treatment chain for major bone and joint diseases (hip, knee, spine) and related orthopaedic surgery. Based on the research of Nobel Physics laureate George Charpak, EOS® is the first imaging solution to capture whole-body 2D and 3D images of standing patients using a very low dose of radiation. The group has been authorised to market its system in 30 countries, including the United States (FDA), Canada, Australia and the European Union. Sales totalled €6.9 million in 2011.

EOS imaging was listed through the admission to trading of 11,882,429[1]existing shares and 5,520,000 new shares issued under a Global Offering,[2] including full exercise of the extension clause. The Global Offering raised a total of €37.9 million, which could rise to €41 million if the greenshoe option is fully exercised.

The admission and issue price of EOS imaging shares was set at €6.87, at the high end of the indicative spread. Market capitalisation stood at around €120 million on the day of listing.

“We are delighted to welcome the EOS imaging group to our European market and, in so doing, play an active role in developing its innovative business. This signals the reopening of listings on the Paris market and illustrates our efforts in the past two years to facilitate financing for businesses, particularly the SMEs that create value and jobs,” said Marc Lefèvre, Head of European Coverage at NYSE Euronext.

Medical technology is one of the world’s fastest growing sectors and offers huge scope for expansion – as investors are well aware. Listing will enable EOS imaging to benefit from the excellent services that NYSE Euronext offers the financial community, and also to diversify its sources of financing as it expands in new geographical regions,” he added.

Marie Meynadier, CEO of EOS imaging, added:“We are very pleased with the success of our public offering. Through listing we have raised the capital we need to step up our international marketing and sales effort and to develop innovative solutions based on the EOS® platform.”

[1]Includes 278,870 new shares created by the redemption in shares, today, at the admission price, of bonds redeemable in shares issued by EOS imaging.

[2]The Global Offering was made up of an Open Price Public Offering and a Global Placement with institutional investors in France and other countries.


Press Release Footer

About Euronext 
Euronext is the leading pan-European market infrastructure, connecting European economies to global capital markets, to accelerate innovation and sustainable growth. It operates regulated exchanges in Belgium, France, Ireland, Italy, the Netherlands, Norway and Portugal. With more than 1,900 listed issuers and around €6.5 trillion in market capitalisation as of end June 2023, it has an unmatched blue-chip franchise and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets, one of Europe’s leading electronic fixed income trading markets and is the largest centre for debt and funds listings in the world. Its total product offering includes Equities, FX, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. The Group provides a multi-asset clearing house through Euronext Clearing, and custody and settlement services through Euronext Securities central securities depositories in Denmark, Italy, Norway and Portugal. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, it also operates a number of junior markets, simplifying access to listing for SMEs.  
For the latest news, follow us on Twitter (twitter.com/euronext) and LinkedIn (linkedin.com/euronext).

This press release is for information purposes only and is not a recommendation to engage in investment activities. This press release is provided “as is” without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext.

This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at www.euronext.com/terms-use.

© 2023, Euronext N.V. - All rights reserved.